அறிவாற்றல் மருந்து ஆராய்ச்சி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from அறிவாற்றல் மருந்து ஆராய்ச்சி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In அறிவாற்றல் மருந்து ஆராய்ச்சி Today - Breaking & Trending Today

Anavex Life Sciences Reports Fiscal 2020 Year End Financial Results And Clinical Program Updates

Anavex Life Sciences Reports Fiscal 2020 Year End Financial Results And Clinical Program Updates
marketwatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketwatch.com Daily Mail and Mail on Sunday newspapers.

United States , Christopheru Missling , Clint Tomlinson , Company Nasdaq , Cognitive Drug Research , Research Business Development , Anavex Life Sciences Corp , Trademark Office , Michaelj Fox Foundation For Parkinson Research , Life Sciences , Chief Executive Officer , Clinical Updates , Fragilex Syndrome , Business Highlights , Rett Syndrome Behaviour Questionnaire , Clinical Global Impression Improvement , Clinical Trials , United States Patent , Annual Report , Anavex Life Sciences , Further Information , ஒன்றுபட்டது மாநிலங்களில் , கிளின்ட் டாம்லின்சன் , நிறுவனம் நாஸ்டாக் , அறிவாற்றல் மருந்து ஆராய்ச்சி , ஆராய்ச்சி வணிக வளர்ச்சி ,

Anavex Life Sciences Reports Fiscal 2020 Year End Financial Results And Clinical Program Updates

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Anavex Life Sciences Reports Fiscal 2020 Year End Financial Results And Clinical Program Updates
Anavex Life Sciences Corp.December 28, 2020 GMT
NEW YORK, Dec. 28, 2020 (GLOBE NEWSWIRE) Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today reported financial results for its fiscal year ended September 30, 2020.
Christopher U Missling, PhD, President and Chief Executive Officer of Anavex said: “Despite all of the new challenges, 2020 was an extraordinary year for Anavex, with significant progress across our portfolio, including our first positive, placebo-controlled, U ....

United States , Christopheru Missling , Clint Tomlinson , Company Nasdaq , Cognitive Drug Research , Research Business Development , Anavex Life Sciences Corp , Trademark Office , Michaelj Fox Foundation For Parkinson Research , Life Sciences , Chief Executive Officer , Clinical Updates , Fragilex Syndrome , Business Highlights , Rett Syndrome Behaviour Questionnaire , Clinical Global Impression Improvement , Clinical Trials , United States Patent , Annual Report , Anavex Life Sciences , Further Information , ஒன்றுபட்டது மாநிலங்களில் , கிளின்ட் டாம்லின்சன் , நிறுவனம் நாஸ்டாக் , அறிவாற்றல் மருந்து ஆராய்ச்சி , ஆராய்ச்சி வணிக வளர்ச்சி ,